Diabetes is a disease characterized by high blood sugar level which is caused by improper functioning of the pancreas, the organ secreting insulin in the body. Diabetic nephropathy is a disease of the kidney glomerulus and happens to be one of the most significant complications in terms of mortality and morbidity for patients with diabetes. The disease is mainly characterized by macroalbuminuria, where in a single day presence of albumin in the urine increases over 300 milligrams. In addition, diabetic nephropathy is also caused by proteinuria, imbalanced glomerular filtration rate, and hypertension. The imbalanced glomerular filtration rate of the kidney builds up waste products in the blood and increases the level of protein in the urine. Signs and symptoms of diabetic nephropathy are unknown in early stage of the disease. However, major signs and symptoms of diabetic nephropathy in its later stages are increased albumin secretion in urine, high blood pressure, ankle and leg swelling, high level of blood urea nitrogen (BUN) and serum creatinine, itching, morning weakness, nausea, vomiting, and anemia. Disease modifying therapies (DMT) that employ angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used in the treatment of diabetic nephropathy. ACE inhibitors, such as enalapril, captopril, ramipril, and lisinopril, lower the amount of protein in the urine. ARBs and ACE inhibitors together provide greater protection to the kidney than they individually can. Major ARBs are candesartan, losartan and irbesartan.
Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.
North America has the largest market for diabetic nephropathy, followed by Europe. Some of the fastest growing markets for diabetic nephropathy are China and Japan. This is due to increase in the diabetic population and rise in incidence rates of various kidney diseases in these countries.
This report provides in-depth analysis and estimation of the diabetic nephropathy market for the period 2014 to 2020, considering 2013 as the base year for calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The diabetic nephropathy market is categorized on the basis of mode of treatment and geography. Based on a mode of treatment for diabetic nephropathy, the market comprises DMT. DMT is further categorised into ACE inhibitors, ARBs, diuretics, calcium channel blockers (CCBs), renin inhibitors, connective tissue growth factor (CTGF) inhibitors, antioxidant inflammation modulators (AIMs), monocyte chemoattractant protein (MCP) inhibitors, endothelin-A receptor (ETAR) antagonist, G protein-coupled receptors (GPCRs), and others. On the basis of geography, the report identifies and analyses the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW).
Some of the major players in the diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie, Inc., and Mitsubishi Tanabe Pharma Corporation. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market intelligence reports. MRRSE is driven by a stellar team of research experts and advisors trained to offer objective advice. Our sophisticated search algorithm returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead of the next new trend in market research, be it competitive intelligence, product or service trends or strategic consulting.
90, State Street
Albany, NY - 12207
Linked in: https://www.linkedin.com/company/mrrse